In vivo observed effects |
miRNA-124a |
Aryl hydrocarbon receptor (AhR) |
Overexpression in CD tissue |
ZO-1 ↓, OCLN ↓, JAM-A ↓, CLDN1 ↓ |
Zhao et al., 2020 [58] |
miRNA-31-5p |
Activin receptor-like type 1 (ALK1) |
Overexpression in CD tissue |
CLDN8 ↓, TJP1 ↓, OCLN ↓ |
Toyonaga et al., 2020 [39] |
miRNA-301A |
B-cell translocation gene 1 (BTG1) |
Overexpression in PBMCs and tissue in IBD |
E-cadherin (AJ) ↓ |
He et al., 2017 [86] |
miRNA-200b |
Myosin light chain kinase (MLCK) and c-JUN |
Decreased in IBD tissue |
ZO-1 ↓, OCLN ↓ |
Shen et al., 2017 [64] |
miRNA-21 |
Claudin 8 (CLDN8) |
Overexpression in CD tissue |
CLDN8 ↓ |
Li et al., 2018 [71] |
miRNA-200c-3p |
Occludin (OCLN) |
Overexpression in UC tissue |
OCLN ↓ |
Rawat et al., 2020 [81] |
miRNA-495 |
Signal transducer and activator of transcription 3 (STAT3) |
Decreased in UC tissue |
CLDN1 ↓ |
Chu et al., 2018 [90] |
miRNA-122a |
Epidermal growth factor receptor (EGFR) |
Overexpression in IBD tissue |
CLDN1 ↓, OCLN ↓, Zonulin ↑ |
Zhang et al., 2017 [92] |
miRNA-320a |
Protein phosphatase 2 (PP2A) and Cell division cycle 42 (Cdc42) |
Overexpression in serum of active CD |
JAM-A ↑ |
Cordes et al., 2016 [106] |
miRNA-423-5p |
CLDN5 |
Overexpression in UC tissue |
CLDN5 ↓ |
Wang et al., 2020 [77] |
In vitro observed effects |
miRNA-185-3p |
Myosin light chain kinase (MLCK) |
Decreased in IBD tissue |
ZO-1 ↓, OCLN ↓ |
Ma et al., 2019 [63] |
miRNA-23a |
Tumor necrosis factor alpha inhibitor protein 3 (TNFAIP3) |
Overexpression in CD tissue |
OCLN destabilization |
Felwick et al., 2020 [33] |
miRNA-675-5p |
Vitamin D receptor (VDR) |
Overexpression in UC tissue |
ZO-1 ↓, OCLN ↓ |
Chen et al., 2016 [52] |
miRNA-375 |
Toll-like receptor 4 (TLR4) |
Decreased in IBD tissue |
ZO-1 ↓, OCLN ↓ |
Wu et al., 2019 [98] |
miRNA-223 |
Claudin 8 (CLDN8) |
Overexpression in IBD tissue |
CLDN8 ↓ |
Wang et al., 2016 [68] |